Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and Its Role in Multidisciplinary Therapy
Authors:
- Marina Ohkoshi-YamadaMOMarina Ohkoshi-Yamada
- Kenya KamimuraKKKenya Kamimura
- Osamu ShibataOSOsamu Shibata
- Shinichi MoritaSMShinichi Morita
- Motoki KaiduMKMotoki Kaidu
- Toshimichi NakanoTNToshimichi Nakano
- Katsuya MaruyamaKMKatsuya Maruyama
- Atsushi OtaAOAtsushi Ota
- Hirotake SaitoHSHirotake Saito
- Nobuko YamanaNYNobuko Yamana
- Tomoya OshikaneTOTomoya Oshikane
- Yukiyo GotoYGYukiyo Goto
Open Access
Abstract
This study investigated the efficacy and safety of radiotherapy as part of multidisciplinary therapy for advanced hepatocellular carcinoma (HCC). Clinical data of 49 HCC patients treated with radiotherapy were assessed retrospectively. The efficacy of radiotherapy was assessed by progression-free survival, disease control rate, and overall survival. Safety was assessed by symptoms and hematological assay, and changes in hepatic reserve function were determined by Child–Pugh score and albumin–bilirubin (ALBI) score. Forty patients underwent curative radiotherapy, and nine patients with portal vein tumor thrombus (PVTT) underwent palliative radiotherapy as part of multidisciplinary therapy. Local disease control for curative therapy was 80.0% and stereotactic body radiotherapy was 86.7% which was greater than that of conventional radiotherapy (60.0%). Patients with PVTT had a median observation period of 651 days and 75% three-year survival when treated with multitherapy, including radiotherapy for palliative intent, transcatheter arterial chemoembolization, and administration of molecular targeted agents. No adverse events higher than grade 3 and no changes in the Child–Pugh score and ALBI score were seen. Radiotherapy is safe and effective for HCC treatment and can be a part of multidisciplinary therapy.Keywords
This publication has 33 references indexed in Scilit:
- Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpointsPractical Radiation Oncology, 2018
- Radiation-Induced Liver ToxicitySeminars in Radiation Oncology, 2017
- Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinomaThe Korean Journal of Internal Medicine, 2016
- Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2015
- Stereotactic Body Radiation Therapy for Liver Cancer: A Review of the TechnologyJournal of Medical Imaging and Radiation Sciences, 2015
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Complications of radiofrequency ablation of hepatic tumors: Frequency and risk factorsWorld Journal of Hepatology, 2014
- Surgical Resection Versus Conformal Radiotherapy Combined With TACE for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Comparative StudyWorld Journal of Surgery, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative StudyAnnals of Surgical Oncology, 2010